This week Harry quizzes Ulo Palm, the senior vice president of digital sciences at Allergan, about the long and problematic reign of the p-value in statistical analysis, and why it may be time for the biopharma industry to look to more nuanced measures of whether a drug trial succeeded.
The content above was previously recorded. The views herein were made at the time of this recording and are not updated to reflect changes in economic or financial circumstances. The opinions are those of the contributor and not Scientia Ventures, LLC, its affiliates, officers, or employees. Nothing herein constitutes a recommendation, solicitation, or offer to purchase securities or private funds, which can only be made through the relevant offering documents.
